Health Discovery Corporation (OTCBB: HDVY) announced today it received the prestigious MICO Award presented by MDB Capital Group, San Francisco, Calif., at its invitation-only Bright Lights Conference held May 11-12, 2010. Health Discovery Corporation was chosen from among 1,600 publicly traded, small cap companies.

The MICO Award is Latin for “to shine.” The award was presented to the Top 5 companies across all industries with the most potentially disruptive or market changing intellectual property. “Disruptive technologies” is a term used in business and technology to describe innovations that improve a product or service in ways that the market does not expect.

According to PatentVest, MDB Capital’s proprietary intellectual property (IP) analytical tool, "Among public companies in the healthcare industry, our IP metrics found that Health Discovery Corporation is a leading innovator of game-changing IP," said Christopher Marlett, Co-Founder, Chairman & CEO, MDB Capital Group.

"Intellectual property is no longer an intangible asset class," said Marlett. "MDB Capital built PatentVest to help investors easily assign a tangible value to patents, and we've proven that market leading IP is predictive of superior business performance. Companies like Health Discovery Corporation typify the market leading IP presented at our Bright Lights Conference," said Marlett.

“Health Discovery Corporation ranks as a market leader in each of the quantitative metrics across the entire health care sector,” said Marlett.

“We are honored to receive the MICO Award from MDB Capital and this independent validation of our market changing intellectual property,” said Stephen D. Barnhill, Chairman and CEO, Health Discovery Corporation.

“The resources invested by MDB Capital in the creation of its rigorous PatentVest analytic tool and applied to our patent portfolio further confirms the value of Health Discovery Corporation’s intellectual property portfolio,” said Dr. Barnhill.

“Companies like Quest Diagnostics, Incorporated (NYSE: DGX) and Abbott Labs (NYSE: ABT) understand the value of Health Discovery Corporation’s patent protected technology and have entered into significant development and commercialization contracts with us,” said Dr. Barnhill. “Our patented technology also attracts world-class scientist-inventors like Isabelle Guyon, Ph.D. and Maher Albitar, M.D. to our company,” said Dr. Barnhill.

“An unsung hero in all of this is our long-time intellectual property lawyer, Eleanor Musick, a partner at the law firm, Procopio, Cory, Hargreaves & Savitch LLP in San Diego, California,” said Dr. Barnhill. “Eleanor’s vast knowledge of patent law, her scientific expertise and strategic thinking and planning have been invaluable in creating the value in our intellectual property portfolio that was recognized publicly by MDB Capital Group selecting HDC for their prestigious MICO Award,” he said.

“I am thrilled to see Health Discovery Corporation receive this honor in recognition of its vision for SVM technology and am happy to have had the opportunity to participate in designing and carrying out a strategy for patent protection of this versatile technology and the valuable discoveries it has produced,” said patent lawyer Eleanor Musick.

“It has been a pleasure working with Health Discovery's impressive inventors and with Dr. Barnhill and his team over the past ten years,” said Musick. “I look forward to working with Health Discovery as it continues its tradition of innovation and to securing additional intellectual property protections for Health Discovery's future inventions and discoveries,” said Musick.

About Health Discovery Corporation

Health Discovery Corporation is a molecular diagnostics company that uses advanced mathematical techniques to analyze large amounts of data to uncover patterns that might otherwise be undetectable. It operates primarily in the emerging field of personalized medicine where such tools are critical to scientific discovery. Its primary business consists of licensing its intellectual property and developing its own product line of biomarker-based diagnostic tests that include human genes and genetic variations, as well as gene, protein, and metabolic expression differences and image analysis in digital pathology and radiology. For more information, see

About Procopio, Cory, Hargreaves and Savitch LLP

With more than 110 attorneys in San Diego and Carlsbad, Calif., Procopio, Cory, Hargreaves and Savitch LLP is one of the largest full-service business law firms in Southern California. Since 1946, the firm's success has been derived from its commitment to its clients and its ability to maximize the value it provides. The firm strives to continue building long-term relationships with its clients through a steady, team-oriented approach. For additional information, please visit

About MDB Capital Group LLC & PatentVest

MDB Capital built PatentVest from the ground up covering over 4,000 public and private companies, unifying over 4 million U.S. patents granted and over 2 million U.S. patent applications on file. Over 75,000 hours and several million dollars were spent on its initial development. Beyond a mere software solution, PatentVest is a fully integrated, easy-to-use online searching, analytic and reporting platform, powered by the world's most comprehensive patent database and a dedicated data center - the first and only one of its kind.

MDB Capital Group LLC is an institutional research and investment banking firm that focuses exclusively on companies that possess market changing, disruptive intellectual property. Member FINRA / SIPC. For more information, see

Forward-Looking Statements

This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, the accuracy of which is necessarily subject to risks and uncertainties, including, without limitation, statements regarding future performance, opportunities and investments, and anticipated results in general. From time to time the Company may make other forward-looking statements relation to other matters, including without limitation, commercialization plans and strategic partnerships. Actual results may differ materially due to a variety of factors, including, among other things, the acceptance of our approach to applying mathematics computer science and physics into the disciplines of biology, organic chemistry and medicine and our products and technologies associated with those approaches, the ability to develop and commercialize new drugs, therapies or other products based on our approaches, and other factors set forth from time to time in the Company’s Securities and Exchange Commission filings.

All forward-looking statements and cautionary statements included in this document are made as of the date hereof based on information available to the Company as of the date hereof, and the Company assumes no obligation to update any forward-looking statement or cautionary statement.

Copyright Business Wire 2010